Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy
- PMID: 18703133
- PMCID: PMC2783360
- DOI: 10.1016/j.bbi.2008.07.010
Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy
Abstract
Cocaine, crack, and methamphetamine are stimulants that promote autonomic nervous system activation. Although these stimulants may have immunomodulatory effects, relatively few studies have examined this possibility. The present cross-sectional investigation utilized baseline data from 127 HIV-positive individuals on anti-retroviral therapy (ART) that were enrolled in a randomized controlled trial. The goal of this study was to examine whether stimulant use is independently associated with immune activation and indices of tryptophan degradation. Forty-four participants reported using stimulants 2-3 times a month or more (i.e., monthly stimulant use) and a sub-set of these (n=27) reported using stimulants once a week or more (i.e., weekly stimulant use) during the past three months. These stimulant-using groups were compared to a group of participants who reported no stimulant use (n=83) during the past three months. Results indicated that individuals who reported either monthly or weekly stimulant use displayed elevated neopterin, a measure of immune activation. Those who reported weekly stimulant use also displayed a markedly elevated HIV viral load and lower tryptophan levels. Even after controlling for self-reported ART non-adherence, weekly stimulant use was independently associated with higher neopterin, elevated HIV viral load, and lower tryptophan. To our knowledge, this is the first study to observe that stimulant use may independently promote immune activation and tryptophan degradation among HIV-positive persons on ART. Further research is needed to replicate these findings and examine the plausible bio-behavioral pathways that may account for the effects of stimulant use on HIV disease markers and depleted tryptophan.
Figures

References
-
- Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG. Adherence-resistance relationships for protease inhibitors and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223–231. - PubMed
-
- Beck AT, Steer RA, Ball R, Ranieri W. Comparison of the Beck Depression Inventories –IA and –II in psychiatric outpatients. Journal of Personality Assessment. 1996;67:588–597. - PubMed
-
- Carrico AW, Chesney MA, Johnson MO, Neilands TB, Remien RH, Rotheram-Borus MJ, Wong FL Healthy Living Project Team. Randomized controlled trial of a cognitive-behavioral intervention for HIV-positive persons: An investigation of treatment effects on psychosocial adjustment. AIDS Behav. in press. - PMC - PubMed
-
- Carrico AW, Johnson MO, Moskowitz JT, Neilands TB, Morin SF, Charlebois ED, Steward WT, Remien RH, Lightfoot MA, Rotheram-Borus MJ, Wong FL, Chesney MA. Affect regulation, stimulant use, and viral load among HIV-positive persons on anti-retroviral therapy. Psychosom. Med. 2007;69:785–792. - PubMed
-
- Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG) AIDS Care. 2000;12:255–266. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous